Epidémiologie et maîtrise de la tuberculose: situation internationale



Similar documents
Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges

Pregnancy and Tuberculosis. Information for clinicians

Childhood Tuberculosis Some Basic Issues. Jeffrey R. Starke, M.D. Baylor College of Medicine

X-Plain Pediatric Tuberculosis Reference Summary

TB CARE EARLY DETECTION AND PREVENTION OF TUBERCULOSIS (TB) IN CHILDREN. Risk factors in children acquiring TB:

TB preventive therapy in children. Introduction

Maria Dalbey RN. BSN, MA, MBA March 17 th, 2015

Tuberculosis Exposure Control Plan for Low Risk Dental Offices

Clinical description 2 Laboratory test for diagnosis 3. Incubation period 4 Mode of transmission 4 Period of communicability 4

Risk for Tuberculosis in Swiss Hospitals. Content. Introduction. Dr. med. Alexander Turk Zürcher Höhenklinik Wald

Health Protection Agency position statement on the use of Interferon Gamma Release Assay (IGRA) tests for Tuberculosis (TB)

Tuberculosis: FAQs. What is the difference between latent TB infection and TB disease?

Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011

Paediatrica Indonesiana. Limitations of the Indonesian Pediatric Tuberculosis Scoring System in the context of child contact investigation

Journal of Infectious Diseases Advance Access published January 26, 2015

Policy Number Date Filed. Subject

Tuberculosis in children in Europe -the ptbnet

Massachusetts Department of Public Health Division of Global Populations and Infectious Disease Prevention

Recent Advances in The Treatment of Mycobacterium Tuberculosis

GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA

Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET

Table. Positive Purified Protein Derivative Results (Pediatrics In Review Apr 2008)

Transmission & Pathogenesis of Tuberculosis

TB Prevention, Diagnosis and Treatment. Accelerating advocacy on TB/HIV 15th July, Vienna

Appendix B: Provincial Case Definitions for Reportable Diseases

TB Intensive San Antonio, Texas November 11 14, 2014

Interim Guidance for Medical Schools on health checks for active and latent Tuberculosis in medical students returning from elective periods overseas

Tuberculosis Transmission in Households and Communities

Summary. Request for Advice

Childhood Tuberculosis: Diagnosis, Treatment and Prevention of TB in HIV-infected Children

ATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS

TB AND M/XDR-TB: FROM CLINICAL MANAGEMENT TO CONTROL AND ELIMINATION

CDC TB Testing Guidelines and Recent Literature Update

Pregnancy and Tuberculosis. Patient and Public information sheet

Santa Clara County Tuberculosis Screening Requirement for School Entrance Effective June 1, Frequently Asked Questions

Policy Directive: compliance is mandatory

Pediatric Latent TB Diagnosis and Treatment

Assisted Living - TB Risk Assessment

Haemophilus influenzaetype b (Hib) Vaccination Position Paper. July 2013

DRAFT FOR CONSULTATION

Regulations for Tuberculosis Control in Minnesota Health Care Settings

TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY. Stephanie N. Lin MD 2/12/2016

How To Calculate The Incidence Of Mycobacterium Tuberculosis

American Thoracic Society Documents

LEARNING OUTCOMES. Identify children at risk of developing TB disease. Correctly manage and refer children suspected of TB. Manage child contacts

PEOSH Model Tuberculosis Infection Control Program

Tuberculosis OUR MISSION THE OPPORTUNITY

Recognised as a world leader and a prominent clinical researcher in South Africa

Contact centred strategies to reduce transmission of M. leprae

TUBERCULOSIS PLEURAL EFFUSION - MANAGEMENT

MANAGEMENT OF TUBERCULOSIS IN PRISONS: Guidance for prison healthcare teams

FEDERAL BUREAU OF PRISONS REPORT ON INFECTIOUS DISEASE MANAGEMENT

Nevada State Health Division Technical Bulletin

How To Treat Tuberculosis

Self-Study Modules on Tuberculosis

ECDC GUIDANCE. Management of contacts of MDR TB and XDR TB patients.

Nurse Aide Training Program Application Checklist

Alcohol abuse and smoking

Long-term Care - TB Risk Assessment


U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention

Tuberculosis. Subject. Goal/Objective. Instructions. Rationale. Operations Directorate, Health Branch Immigration Medical Examination Instructions

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

Perils and Pitfalls in Clinical Trials of Diagnostic Tests for Tuberculosis. Richard O Brien, MD Foundation for Innovative New Diagnostics Geneva

Screening and preventive therapy for MDR/XDR-TB exposed/infected children (and adults)

What is an IGRA? What is an IGRA? Are they available here? How do I use them? Learning Objectives

Mycobacteriosis and HIV infection: the new public health challenge

Guideline. Treatment of tuberculosis in patients with HIV co-infection. Version 3.0

THE NATURAL HISTORY OF PULMONARY TUBERCULOSIS

2011 NTP Paediatric guidelines update- final draft

Diagnostic Testing and Strategies for BVDV

TUBERCULOSIS the disease, its treatment and prevention. mmunisation

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

Lisa Y. Armitige, MD, PhD has the following disclosures to make:

Core Curriculum on Tuberculosis: What the Clinician Should Know Sixth Edition 2013

What is HIV? What is AIDS? The HIV pandemic HIV transmission Window period Stages of HIV infection

100% WHEY PROTEIN PARTIALLY HYDROLYZED in Infant Formula and REDUCING THE RISK OF ALLERGY IN INFANTS EXECUTIVE SUMMARY

Challenges in Pediatric Tuberculosis. Mimi Emig, MD Spectrum Health Kent County Health Department

TUBERCULOSIS CONTROL INDIA

Tuberculousmeningitis: what is the best treatment regimen?

Daniel Chemtob MD MPH DEA 1,2, Daniel Weiler-Ravell MD 1,2, Alex Leventhal MD MPH MPA 2 and Haim Bibi MD 3. Patients and Methods Case studies

San Francisco Treatment Guidelines for Latent Tuberculosis Infection

Management of a child failing first line TB treatment.

Guidelines on targeted tuberculin testing and treatment of latent tuberculosis infection

Tuberculosis. TB the disease, its treatment and prevention

Tuberculosis the disease, its treatment TBand prevention

The Burgeoning Public Health Crisis: Demand Analysis and Market Opportunity for Advanced Trauma Systems in the Developing World

Tuberculosis Prevention and Control Protocol, 2008

Exercise Answers. Exercise B 2. C 3. A 4. B 5. A

Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management

No. prev. doc.: 8770/08 SAN 64 Subject: EMPLOYMENT, SOCIAL POLICY, HEALTH AND CONSUMER AFFAIRS COUNCIL MEETING ON 9 AND 10 JUNE 2008

Dr Malgosia Grzemska Global TB programme, WHO/HQ Meeting of manufacturers Copenhagen, Denmark, November 2015

Immuno-Oncology Therapies to Treat Lung Cancer

Background paper for SAGE discussions. SAGE non-specific effects of vaccines Working Group

TRACKS INFECTIOUS DISEASE EPIDEMIOLOGY

Tuberculosis (TB) Screening Guidelines for Substance Use Disorder Treatment Programs in California

Prevention of Acute COPD exacerbations

The Effectiveness of Hot Hypochlorite Solutions to destroy M tuberculosis

Notes. Complete childhood vaccination course (CCV) CCV and DTP booster as adolescent/adult within last 10 years

General Information on Tuberculosis

Transcription:

Epidémiologie et maîtrise de la tuberculose: situation internationale Paris, 24 mars 2009 Hans L Rieder Union Internationale Contre la Tuberculose et les Maladies Respiratoires

Relationship between estimated tuberculosis incidence rates 2004 and per capita gross domestic product 2005 Tuberculosis cases per 100,000 (log scale) 1,000 500 200 100 50 20 10 5 India China France 2.5 100 200 500 1,000 2,000 5,000 10,000 20,000 50,000 GDP (in US$) per head (log scale) Janssens JP, Rieder HL. Eur Respir J 2008;32:1415-6

Using a common terminology Exposure Infection Disease Death A non-infected individual is inhaling air that contains a sufficient number of M. tuberculosis as to ensure a reasonably measurable probability of inhaling at least one infecting dose An exposed individual that has inhaled an infecting dose of M. tuberculosis that has resulted in sub-clinical replication of the latter the individual has latent (sub-clinical) infection with viable M. tuberculosis An infected individual which is unable to contain replication of M. tuberculosis to a number that causes clinically manifest tuberculosis An individual with tuberculosis who is unable to control replication of M. tuberculosis so that the resulting damage kills the host

In tuberculosis pathogenesis, the incubation period (between infection and manifest disease) is not defined and there is only partial protective immunity against reinfection

Incident cases of tuberculosis emerge unpredictably from the population prevalently infected with M tuberculosis Population including persons with and without infection with M tuberculosis

Transmission Chemotherapy Doctor's delay Prophylactic treatment Preventive therapy Patient's delay Infectious tuberculosis Exposure Subclinical infection Non-infectious tuberculosis Death BCG vaccination

An Epidemiologic Approach to Tuberculosis Interventions Reduction of the incidence of tuberculous infection Essence of the tuberculosis control strategy: identification and curative chemotherapy for cases transmitting M. tuberculosis Reduction of the prevalence of tuberculous infection Component of the tuberculosis elimination strategy: identification and preventive chemotherapy for persons already infected

Mantoux C. La Presse Médicale 1910;2:10-15

100 Age-Specific Prevalence of Tuberculous Infection in Healthy Children, Paris, 1910 Per cent reacting 80 60 40 20 0 0 5 10 15 Age (years) Mantoux C. Presse Méd 1910;2:10-13

Childhood experience predicts adult experience in every birth cohort! Mortality Andvord K F. Norsk Magasin for Lægevidenskaben 1930;91:642-60

Fate of M tuberculosis in calcified lesions Author Schmitz Rabinowitch Koenigsfeld Schroeder Opie Griffith Rubinstein Anders Saenz Total Pulmonary Lesions Sterile 10 9 - - 21 17 40 40 92 77 - - 27 16 - - 44 33 234 192 Lymphatic Lesions Sterile 16 10 30 19 18 13 61 60 91 70 17 17 - - 58 50 - - 291 239 Percentage sterile 82.1 82.1 Canetti G. Paris: Vigot Frères, 1939, 305 pp

Once infected always infected : A hypothesis not borne out by facts Kristian Andvord s observation: A case for prolonged latency with subsequent reactivation, but. George Canetti s findings tell otherwise: The immune system leads to killing of tubercle bacilli

1000 Growth of BCG in mice after sub-cutaneous vaccination 500 Spleen 300 CFU of BCG 100 50 30 Lymph nodes Lung 10 0 1 2 3 4 5 Month after BCG vaccination Olsen AW, et al. Scand J Immunol 2004;60:273-77

Protection Afforded by BCG Vaccination in British School Children During Follow-up 100 80 Protection (%) 60 40 20 0 0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0 Year of follow-up D'Arcy Hart P, et al. Br Med J 1977;2:293-5

The Koch Phenomenon A primary infection leads to a delayed response and has often a mild and self-limited course A reinfection results commonly in a rapid response with tissue necrosis Drawings: Koch R. Mittheilungen aus dem Kaiserlichen Gesundheitsamte 1884;2:1-88. Phenomenon: Koch R. Dtsch Med Wochenschr 1891;17:101-2.

1930: Andvord Birth cohort Cross-sectional Age Morbidity / mortality Primary infection Primary infection 1891: Koch Progressive Re-infection Time 1939: Canetti Re-infection Time / age Abortive 1977: BMRC BCG Trial Time Remaining live bacilli Tissue destruction BCG protection

Occam s razor? o o o A first infection is commonly overcome and frequently ends in the elimination of bacilli but primes the immune system for a decade or more A primed immune system may protect against subsequent re-infection or alternatively results in a severe tissue damaging response A positive tuberculin skin test is neither expression of living bacilli nor of protective immunity, it only reflects the immunologic response following prior infection

Incidence Case Rate Among Household Contacts of Smear- Positive Tuberculosis, by Intitial Tuberculin and IGRA Test, Gambia Incidence per 100,000 p-yr 2000 1500 1000 500 100 Mx: ES: Mx- ES- Mantoux Elispot 0.8-1.3%! Mx- ES- Mx+ Mx+ ES- ES+ Mx- ES+ Mx+ ES+ Mx+ or ES+ Hill PC, et al. PLoS One 2008;3(1): e1379. doi:10.1371/journal.pone.0001379

A simplified view of a problem: Tuberculin skin test versus IGRAs Both tests measure the wrong thing, but IGRAs do it more specifically An immunologic response to mycobacterial antigens acquired in the past does not equate currently live bacilli ready to cause disease (BCG!)

400 Preventive Therapy for HIV Infected Police Officers in Dar es Salaam, Tanzania HIV+ Number of persons 300 200 100 Got result Accept PT Evaluated Started INH Adherent 0 Bakari M, et al. East Afr Med J 2000;77:494-7

Tuberculosis Incidence in an HIV-Infected Cohort of Patients on Anti-Retroviral Therapy, Switzerland, 1996-2005 6000 Number of Patients 5000 4000 3000 2000 1000 0 Cohort HIV pos <5mm >=5mm Prev ther Subjects 6,018 4,168 390 144 Missed 30 10 16 0 Averted 0 0.1 0.2 9.4 Total 56 9.7 Elzi L, et al. Clin Infect Dis 2007;44:94-102

Exposure Subclinical infection Effectiveness of BCG Against Meningeal Tuberculosis, Meta-Analysis of Case-Control Studies, 1947-1993 Buenos Aires, 1988 São Paulo, 1990/93 Bahia, 1991 São Paulo, 1990/93 Nagpur, 1996 Delhi, 1989 Bela Horizonte, 1988 Chennai, 1996 Summary measure Bela Horizonte, 1965 Delhi, 1964 Papua New Guinea, 1958 Delhi, 1956 Yangon, 1952 Lucknow, 1947 Infectious tuberculosis Non-infectious tuberculosis -40 0 20 50 80 90 Per cent protection (log scale) Bourdin Trunz B, et al. Lancet 2006;367:1173-80 BCG vaccination but tuberculous meningitis is no more the biggest concern in Europe

Transmission Chemotherapy Doctor's delay Prophylactic treatment Preventive therapy Patient's delay Infectious tuberculosis Exposure Subclinical infection Non-infectious tuberculosis Death BCG vaccination

Fate of Untreated Pulmonary Tuberculosis in Sanatorium Patients, Long-Term Follow-Up, Barmelweid, Switzerland 100 80 "Open" tuberculosis Per cent dead 60 40 20 "Closed" tuberculosis 0 0 2 4 6 8 10 12 14 16 18 Years after first admission Krebs W. Beitr Klin Tbk 1930;74:345-79

Fraction of cases / infected 1.0 0.8 0.6 0.4 0.2 0.0 Sensitivity of Direct Sputum Smear Examination in Identifying Pulmonary Tuberculosis and Transmitters Smear-neg Culture-pos Smear-pos Culture-pos Cases of pulmonary tuberculosis Infected contacts < 15 yr Fraction due to smear-neg cases Fraction due to smear-pos cases Calculated from data from: Grzybowski S, et al. Bull Int Union Tuberc Lung Dis 1975;50:90-106

Schematic Presentation of Relative Frequency of Patients, Number of bacilli, and Available Diagnostic Methods Improve identification of transmitters: = Improve microscopy Frequency Improve identification of patients: = Improve clinical skills 0 1 10 100 1000 10.000 100.000 1.000.000 AFB per ml of sputum Poor microscopy (35%) Excellent microscopy (65%) PCR (80%) Culture (85%) X-Ray and clinical (15%) Slide courtesy: Van Deun A, November 22, 2007

Miliary Tuberculosis After 2 months chemotherapy After 6 months chemotherapy